abametapir lice
Selected indexed studies
- Abametapir for the Treatment of Head Lice: A Drug Review. (Ann Pharmacother, 2022) [PMID:34157881]
- Abametapir 0.74% (Xeglyze) for the Treatment of Head Lice. (Am Fam Physician, 2022) [PMID:35839355]
- Effect of a New Head Lice Treatment, Abametapir Lotion, 0.74%, on Louse Eggs: A Randomized, Double-Blind Study. (Glob Pediatr Health, 2019) [PMID:30828591]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Abametapir for the Treatment of Head Lice: A Drug Review. (2022) pubmed
- Abametapir 0.74% (Xeglyze) for the Treatment of Head Lice. (2022) pubmed
- Effect of a New Head Lice Treatment, Abametapir Lotion, 0.74%, on Louse Eggs: A Randomized, Double-Blind Study. (2019) pubmed
- Ovicidal Efficacy of Abametapir Against Eggs of Human Head and Body Lice (Anoplura: Pediculidae). (2017) pubmed
- Drugs for head lice. (2024) pubmed
- Abametapir: A New Solution to an Age Old Problem. (2024) pubmed
- Common pediatric infestations: update on diagnosis and treatment of scabies, head lice, and bed bugs. (2021) pubmed
- Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation. (2018) pubmed
- New chemistries for the control of human head lice, Pediculus humanus capitis: A mini-review. (2022) pubmed
- Treatment failure of over-the-counter pediculicide shampoos in Thai schoolgirls: Evidence of insecticide resistance. (2025) pubmed